VRDN
Viridian Therapeutics Inc
NASDAQ: VRDN · HEALTHCARE · BIOTECHNOLOGY
$13.48
+1.35% today
Updated 2026-04-30
Market cap
$1.37B
P/E ratio
—
P/S ratio
19.35x
EPS (TTM)
$-3.32
Dividend yield
—
52W range
$12 – $34
Volume
2.3M
Viridian Therapeutics Inc (VRDN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-95,643.00%
ROE
-49.20%
ROA
-27.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $4.41M | $-7.21M | 30.95% | -91.40% | -163.67% |
| 2013 | $4.32M | $-2.16M | 42.11% | -4.55% | -50.03% |
| 2014 | $4.32M | $-7.89M | 24.93% | -158.96% | -182.64% |
| 2015 | $2.54M | $-11.33M | 2.60% | -440.78% | -446.34% |
| 2016 | $3.34M | $-12.67M | 23.64% | -374.83% | -379.80% |
| 2017 | $4.00M | $-26.51M | -390.21% | -662.80% | -662.30% |
| 2018 | $8.39M | $-32.70M | -262.76% | -394.51% | -389.97% |
| 2019 | $4.46M | $-41.87M | 100.00% | -941.02% | -938.65% |
| 2020 | $1.05M | $-110.72M | -2,595.62% | -10,512.38% | -10,544.29% |
| 2021 | $2.96M | $-79.41M | 100.00% | -2,690.79% | -2,680.16% |
| 2022 | $1.77M | $-129.87M | 100.00% | -7,579.23% | -7,329.23% |
| 2023 | $314000.00 | $-237.73M | 100.00% | -81,035.03% | -75,711.46% |
| 2024 | $302000.00 | $-269.95M | 100.00% | -99,018.21% | -89,387.09% |
| 2025 | $70.85M | $-342.60M | 98.36% | -512.91% | -483.57% |